Evidence map›Paper›PMID 38535549›Full record

ArticlePathogens (Basel, Switzerland)2024

Genomic Insights into

Natalia Gómez-Casanova, Mª Nieves Gutiérrez-Zufiaurre, Ana Mª Blázquez de Castro, Juan Luis Muñoz-Bellido

Open access · goldAbstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Emerging microbes & infections · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Natalia Gómez-CasanovaResearch Group on Clinical Microbiology and Parasitology and Antimicrobial Resistance (IIMD-16), Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, CSIC, Hospital Universitario de Salamanca, 37007 Salamanca, Spain.ORCID 0000-0002-6983-1895
Mª Nieves Gutiérrez-ZufiaurreResearch Group on Clinical Microbiology and Parasitology and Antimicrobial Resistance (IIMD-16), Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, CSIC, Hospital Universitario de Salamanca, 37007 Salamanca, Spain.
Ana Mª Blázquez de CastroResearch Group on Clinical Microbiology and Parasitology and Antimicrobial Resistance (IIMD-16), Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, CSIC, Hospital Universitario de Salamanca, 37007 Salamanca, Spain.
Juan Luis Muñoz-BellidoResearch Group on Clinical Microbiology and Parasitology and Antimicrobial Resistance (IIMD-16), Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, CSIC, Hospital Universitario de Salamanca, 37007 Salamanca, Spain.ORCID 0000-0002-5981-8785
Universidad de Salamanca · ES

Funding

Gerencia Regional de Salud, Consejería de Sanidad, Junta de Castilla y León. Grant GRS 1831/A/18,
6 · The paper itself

Abstract

Daptomycin is one of the last therapeutic resources for multidrug-resistant gram-positive bacteria. Despite its structural similarities with glycopeptides, its mechanisms of action and resistance are different and in some respects are not completely understood. Mutations in several genes have been associated with daptomycin resistance, especially in

Indexed as

Anti-Bacterial AgentsDaptomycinMicrobial Sensitivity TestsStaphylococcal InfectionsStaphylococcus aureusBacterial ProteinsDrug Resistance, BacterialGenome, BacterialHumansMutationAnti-Bacterial AgentsBacterial ProteinsDaptomycindaptomycinmutationsresistanceStaphylococcus aureus

Identifiers

PMID38535549
PMCPMC10974884
OpenAlexW4392166790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.